2.50
Hdl Handle:
http://hdl.handle.net/10541/108145
Title:
Targeted molecular mechanisms of epoetin alfa.
Authors:
Langer, Corey J; Hirsch, Fred R; Cortés-Funes, Hernan; Sawyer, Stephen T; Thatcher, Nick
Abstract:
Despite therapeutic improvements and ongoing efforts to develop more efficacious therapies, the majority of lung cancer patients face a poor prognosis. Therefore, the primary goal of current treatment is palliation, improvement and maintenance of quality of life (QOL), and (modest) prolongation of survival. Anemia frequently occurs in lung cancer patients and has been associated with decreased QOL, impaired treatment outcomes, and shortened survival time. Furthermore, anemia is a causative factor of tumor hypoxia, which compromises the efficacy of chemotherapy and radiotherapy. Thus, correction of even mild anemia seems to have a beneficial effect on QOL and cancer treatment outcomes. The current article describes the basis and mechanism for the use of recombinant human erythropoietin (rHuEPO, epoetin alfa), a molecular targeted therapy, for the treatment of cancer-related anemia, with a focus on lung cancer. Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. In addition, emerging data show that epoetin alfa may offer potential benefits beyond treating anemia, specifically in terms of treatment outcomes and cognitive function. Future research needs to be conducted to explore the potential for epoetin alfa to improve survival time in lung cancer patients.
Affiliation:
Department of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. cj_langer@fccc.edu
Citation:
Targeted molecular mechanisms of epoetin alfa. 2003, 41 Suppl 1:S133-45 Lung Cancer
Journal:
Lung Cancer
Issue Date:
Aug-2003
URI:
http://hdl.handle.net/10541/108145
DOI:
10.1016/S0169-5002(03)00157-0
PubMed ID:
12867072
Type:
Article
Language:
en
ISSN:
0169-5002
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorLanger, Corey Jen
dc.contributor.authorHirsch, Fred Ren
dc.contributor.authorCortés-Funes, Hernanen
dc.contributor.authorSawyer, Stephen Ten
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-22T09:19:56Z-
dc.date.available2010-07-22T09:19:56Z-
dc.date.issued2003-08-
dc.identifier.citationTargeted molecular mechanisms of epoetin alfa. 2003, 41 Suppl 1:S133-45 Lung Canceren
dc.identifier.issn0169-5002-
dc.identifier.pmid12867072-
dc.identifier.doi10.1016/S0169-5002(03)00157-0-
dc.identifier.urihttp://hdl.handle.net/10541/108145-
dc.description.abstractDespite therapeutic improvements and ongoing efforts to develop more efficacious therapies, the majority of lung cancer patients face a poor prognosis. Therefore, the primary goal of current treatment is palliation, improvement and maintenance of quality of life (QOL), and (modest) prolongation of survival. Anemia frequently occurs in lung cancer patients and has been associated with decreased QOL, impaired treatment outcomes, and shortened survival time. Furthermore, anemia is a causative factor of tumor hypoxia, which compromises the efficacy of chemotherapy and radiotherapy. Thus, correction of even mild anemia seems to have a beneficial effect on QOL and cancer treatment outcomes. The current article describes the basis and mechanism for the use of recombinant human erythropoietin (rHuEPO, epoetin alfa), a molecular targeted therapy, for the treatment of cancer-related anemia, with a focus on lung cancer. Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. In addition, emerging data show that epoetin alfa may offer potential benefits beyond treating anemia, specifically in terms of treatment outcomes and cognitive function. Future research needs to be conducted to explore the potential for epoetin alfa to improve survival time in lung cancer patients.en
dc.language.isoenen
dc.subjectAnaemiaen
dc.subjectHaematinicsen
dc.subjectLung Canceren
dc.subject.meshAnemia-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshCognition-
dc.subject.meshEpoetin Alfa-
dc.subject.meshHematinics-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshPalliative Care-
dc.subject.meshQuality of Life-
dc.subject.meshSurvival Analysis-
dc.subject.meshTreatment Outcome-
dc.titleTargeted molecular mechanisms of epoetin alfa.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA. cj_langer@fccc.eduen
dc.identifier.journalLung Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.